A Bayesian Adaptive Design with Biomarkers for Targeted Therapies and Some Commentary on Adaptive Designs
Seminar Room 1, Newton Institute
AbstractPharmacogenomic biomarkers are considered an important component of targeted therapies as they can potentially be used to identify patients who are more likely to benefit from them. New study designs may be helpful which can evaluate both the prognosis based on the biomarkers and the response from targeted therapies. In this talk I will present a recently developed Bayesian response-adaptive design. The design utilizes individual pharmacogenomic profiles and clinical outcomes as they become available during the course of the trial to assign most effective treatment to patients. I will present simulation studies of the proposed design. In closing I will share my perspectives on adaptive designs in general.
If it doesn't, something may have gone wrong with our embedded player.
We'll get it fixed as soon as possible.